Navigation Links
Identity™ SR 5172

ProductsIdentity™ SR 5172
Company St. Jude Medical, Inc.
Item Identity™ SR 5172
Features 
  • Single-chamber, rate-responsive pacemaker
  • Stored electrograms (EGMs)
  • Beat-by-Beat AutoCapture Pacing Systems
  • Omnisense accelerometer sensor
  • Connector that accepts all unipolar and bipolar IS-1 3.2 mm short-terminal pin leads
  • Automatic P & R wave measurements
  • Advanced hysteresis response
  • Cellular Tested
Description The Identity pacemaker family, which includes the world's smallest dual-chamber pacemaker, provides clinicians with the most advanced pacemaker technology available, including the revolutionary AF Suppression algorithm, the first and only U.S. commercially approved algorithm designed to suppress atrial fibrillation (AF). The AF Suppression algorithm in the Identity pacemaker family is combined with the most advanced diagnostic systems and bradycardia feature set available today, establishing the Identity pacemaker as the premier product offering in complete arrhythmia care.
Info St. Jude Medical, Inc.
Customer Service: (800) 328-9634
Web site: http://www.sjm.com

Related medicine products :

1. Identity™ DR 5370
2. Identity™ XL 5376
...ears -- and works! Baby Gender Mentor Home DNA Gen...nology to attain the earliest gender detection wit...cy. The technique traces the amount of Y chromosom...Here's how it works: Your baby releases its DNA in...
...roducts, ,Westmed designs, manufacturers and mark... and Respiratory professionals. Our mission is to ...linician's ability to deliver quality medical care..., ,Our web site is designed with our customers in...
...mbrane glycoprotein associated with tyrosine kinas...ancer show an amplification and/or over-expression...on of Herceptin® as a targeted therapy for bre...reast carcinoma has become very important in patie...
...roducts, ,Westmed designs, manufacturers and mark... and Respiratory professionals. Our mission is to ...linician's ability to deliver quality medical care..., ,Our web site is designed with our customers in...
Medicine Products:
(Date:11/25/2009)...BroadPoliticalEndorsements,Business,andPressJoinEf...re-USNewswire/--Onceagain,theNationalBipolarFounda...endorsingtheir"Safe,tilStable"program,whichisnowbe...bipolardisorder.Today,theNationalBipolarFoundation...sPriorityMailfromtheLt.GovernorofLouisianaMitchLan...
(Date:11/25/2009)...tuitous discovery that grew out of a collaboration...tially offer hope to the nearly 10 million America... , Also known as hardening of the arteries, per...ulatory problem in which narrowed arteries reduce ...ed a red flag for vascular disease, heart attack a...
(Date:11/25/2009)..., already used to fight rheumatoid arthritis, coul... , WEDNESDAY, Nov. 25 (HealthDay News) -- A...a and rheumatoid arthritis now also shows some pro... 1 diabetes. , The drug, rituximab (Rituxan), h...sulin, even though the disease had destroyed some ...
(Date:11/25/2009)... often plagued by neurological symptoms, study fin...ws) -- Neurological side effects are among the pot...sticular cancer who were treated with cisplatin-ba...study included 1,409 Norwegian men treated for uni...o took part in a follow-up survey conducted from 1...
(Date:11/25/2009)...RLINGTON,Va.,Nov.25/PRNewswire-USNewswire/--TheAme...ealthCareFraudActof2009,"S.2128,whichisdesignedtos...ventfraudinMedicare.ThebillwasintroducedbySen.Geor...eralprovisionstheAmericanAssociationforHomecareout...ociationproposedtoCongressinFebruary.Thoseprovisio...
Breaking Medicine News(10 mins):Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3Health News:American Association for Homecare Endorses New U.S. Senate Bill, the 'Prevent Health Care Fraud Act of 2009' 2
...echniques of soft condensed matter physics, a rese...finely tuned balance of attractions between protei... even a small change in this balance can cause pro...gregation diseases (such as Alzheimers disease), a...
...007) New research published in the November issue...s shows that urban colorectal and lung cancer pati... patients do. This finding is contrary to the com...nts presenting with metastatic cancer is alarming,...
... 9 Hooper Holmes,Inc. (Amex: HH ), a leading pro...unced financial results for the third quarter ende...were $56.3 million compared to $60.6,million in th... loss of $42.1 million or $(0.63) per share in the...
... Pharmaceutical product teams,have the power to m...lem is,launch teams often lack the right structure...fore only produce a sub-optimal launch. In fact, ...ialization. According to a study by pharmaceutical...
...y Distributing over 12 Million Narcotic Pain,Pills...ney Matt M. Dummermuth announced today that six me...istribute controlled substances through an,Interne... Rapids. The indictment also seeks forfeiture of m...
...now be mapped less to mathematical standards and m...y by researchers at Harvard and Johns Hopkins Univ...onal Biology on November 9, 2007, provides a new p...cancer has long been based on streamlined models w...
Other Medicine News:Health News:Physics provides new insights on cataract formation 2Health News:Study reveals differences in cancer stage presentation between rural and urban patients 2Health News:Hooper Holmes Announces Third Quarter 2007 Results 2Health News:Hooper Holmes Announces Third Quarter 2007 Results 3Health News:Hooper Holmes Announces Third Quarter 2007 Results 4Health News:Hooper Holmes Announces Third Quarter 2007 Results 5Health News:Hooper Holmes Announces Third Quarter 2007 Results 6Health News:Hooper Holmes Announces Third Quarter 2007 Results 7Health News:Pharmaceutical Product Commercialization: Enabling Teams to Excel 2Health News:Pharmaceutical Product Commercialization: Enabling Teams to Excel 3Health News:$40 Million Forfeiture Sought in Nation-Wide Internet Pharmacy Case 2
(Date:11/25/2009)...rstCall/--Pharmasset,Inc.(Nasdaq: VRUS ),aclinical...evelopingandcommercializingnoveldrugstotreatvirali...endedSeptember30,2009.AtSeptember30,2009Pharmasset...investments. ,, PipelineUpdateand2009Highlight...ateNovember2009,anindependentDataMonitoringCommitt...
(Date:11/25/2009)...PRNewswire/-- FromNovember16-18,Phonak,theleadingm...hesecondeditionoftheHearingCareforAdultsConference...conferencebroughttogetherleadingexpertsinaginganda...whoworkeverydaywitholderpeoplewithhearinglossforan...searchandtrendsinhearingcareforolderpeople. ,,...
(Date:11/25/2009)...--TheFDAgrantedtraditionalapprovalforINTELENCE...riptaseinhibitor(NNRTI).INTELENCEistheonlyNNRTIspe...ltswhoareexperiencingvirologicfailurewithHIV-1stra...ents.Thetraditionalapprovalisbasedon48-weekdatafro...scurrentlymarketedintheU.S.byTibotecTherapeutics,a...
Breaking Medicine Technology:Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 4Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection 28CDI 29 5005 1Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection 28CDI 29 5005 2Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection 28CDI 29 5005 3Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection 28CDI 29 5005 4Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection 28CDI 29 5005 5Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection 28CDI 29 5005 6The Celebrate Wellness Expo Presents Motivational Speaker 26 Author Dr Robin L Smith and Spiritual Teacher 26 Author Rev Michael Bernard Beckwith 57249 1The Celebrate Wellness Expo Presents Motivational Speaker 26 Author Dr Robin L Smith and Spiritual Teacher 26 Author Rev Michael Bernard Beckwith 57249 2ATS Medical to Participate at the 2009 UBS Global Life Sciences Conference 57246 1ATS Medical to Participate at the 2009 UBS Global Life Sciences Conference 57246 2